NMD4C Launch Canadian Neuromuscular Clinical Trial Database

The NMD4C are excited to launch the The Canadian Neuromuscular Clinical Trial Database to provide a comprehensive and reliable landscape of Canadian neuromuscular clinical trials. The trial database is an initiative of the NMD4C Clinical Trial Network (CTN) created in collaboration with Canadian neuromuscular clinical trial site teams. Monthly updates are provided by clinical research coordinators working at Canadian trial sites, ensuring the most current information is always available.

View the database here!

The Canadian Neuromuscular Clinical Trial Database has been designed to meet the needs of Canadian neuromuscular trial community stakeholders.

  • Providing accurate and up-to-date information: Our database provides reliable details about recruiting and not yet recruiting neuromuscular clinical trials, including clinical trial site locations and contact information.
  • Fostering collaboration: Enables investigators to identify other sites conducting the same trial at different locations, fostering collaboration to address challenges and share best practices,
  • Streamlining patient referral: Can be used as a tool to facilitate patient referral to appropriate clinical trials and/or clinical sites.

The database will continue to be updated and expanded. If you have any questions about the Canadian Neuromuscular Clinical Trial Database or would like to add your site to our list, please contact CTN manager Dr. Maria Masnata.

The NMD4C CTN is led by Dr. Craig Campbell, Dr. Jean Mah, and Dr. Kerri Schellenberg, with the objectives of increasing the number of clinical trials in Canada, enhance Canadian sites’ trial capacity, and support a cohesive network of clinician researchers and their teams.

Canadian Neuromuscular Clinical Trial Database

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.